Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC Transplantation for Decompensated Hepatitis B Cirrhosis
NCT05106972Recruiting
- Sponsor
- Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of human umbilical cord mesenchymal stem cells in Liver cirrhosis (LC), sponsored by Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. Primary endpoints: Total bilirubin at 72 weeks, Albumin at 72 weeks and 2 more. Started Dec 2021; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT05106972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106972.